AU2012312126B2 - Vaccine therapy - Google Patents

Vaccine therapy Download PDF

Info

Publication number
AU2012312126B2
AU2012312126B2 AU2012312126A AU2012312126A AU2012312126B2 AU 2012312126 B2 AU2012312126 B2 AU 2012312126B2 AU 2012312126 A AU2012312126 A AU 2012312126A AU 2012312126 A AU2012312126 A AU 2012312126A AU 2012312126 B2 AU2012312126 B2 AU 2012312126B2
Authority
AU
Australia
Prior art keywords
antigenic peptide
memory
peptide
syndrome
aci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012312126A
Other languages
English (en)
Other versions
AU2012312126A1 (en
Inventor
Pavel Belichenko Vasilyevich
Rime MADANI
William Charles Mobley
Andreas Muhs
Andrea Pfeifer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AC Immune SA
Original Assignee
AC Immune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AC Immune SA filed Critical AC Immune SA
Publication of AU2012312126A1 publication Critical patent/AU2012312126A1/en
Application granted granted Critical
Publication of AU2012312126B2 publication Critical patent/AU2012312126B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2012312126A 2011-09-23 2012-09-21 Vaccine therapy Active AU2012312126B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2011/052992 2011-09-23
USPCT/US2011/052992 2011-09-23
PCT/US2012/056728 WO2013044147A1 (en) 2011-09-23 2012-09-21 Vaccine therapy

Publications (2)

Publication Number Publication Date
AU2012312126A1 AU2012312126A1 (en) 2014-03-27
AU2012312126B2 true AU2012312126B2 (en) 2016-11-10

Family

ID=47018510

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012312126A Active AU2012312126B2 (en) 2011-09-23 2012-09-21 Vaccine therapy

Country Status (23)

Country Link
US (2) US20140314837A1 (cg-RX-API-DMAC7.html)
EP (1) EP2758071B1 (cg-RX-API-DMAC7.html)
JP (1) JP6110861B2 (cg-RX-API-DMAC7.html)
KR (3) KR20160099732A (cg-RX-API-DMAC7.html)
CN (2) CN104039346A (cg-RX-API-DMAC7.html)
AU (1) AU2012312126B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014006871A2 (cg-RX-API-DMAC7.html)
CA (1) CA2811188C (cg-RX-API-DMAC7.html)
DK (1) DK2758071T3 (cg-RX-API-DMAC7.html)
EA (1) EA032494B1 (cg-RX-API-DMAC7.html)
ES (1) ES2712951T3 (cg-RX-API-DMAC7.html)
HU (1) HUE041277T2 (cg-RX-API-DMAC7.html)
IL (1) IL231564A0 (cg-RX-API-DMAC7.html)
MX (1) MX350928B (cg-RX-API-DMAC7.html)
MY (1) MY169574A (cg-RX-API-DMAC7.html)
PH (1) PH12014500657A1 (cg-RX-API-DMAC7.html)
PL (1) PL2758071T3 (cg-RX-API-DMAC7.html)
PT (1) PT2758071T (cg-RX-API-DMAC7.html)
SG (1) SG11201400795UA (cg-RX-API-DMAC7.html)
SI (1) SI2758071T1 (cg-RX-API-DMAC7.html)
TR (1) TR201901846T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013044147A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201402071B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽,抗Tau抗体,及其使用方法
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
CN113853214A (zh) * 2019-05-21 2021-12-28 Ac免疫有限公司 抗Aβ疫苗治疗
WO2024156912A1 (en) 2023-01-26 2024-08-02 Ac Immune Sa Anti-abeta vaccine therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068411A2 (en) * 2005-12-12 2007-06-21 Ac Immune S.A. Therapeutic vaccine
WO2010106127A2 (en) * 2009-03-18 2010-09-23 Ac Immune S.A. Method for therapeutic use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009831A1 (en) 1997-08-28 1999-03-04 Ajay North America Methods and compositions for protecting plants and crops
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
SI2336147T1 (sl) * 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
AU2005290250A1 (en) * 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
CA2690434C (en) * 2007-06-12 2018-05-22 Ac Immune S.A. Monoclonal anti beta amyloid antibody
EP2632434B1 (en) * 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068411A2 (en) * 2005-12-12 2007-06-21 Ac Immune S.A. Therapeutic vaccine
WO2010106127A2 (en) * 2009-03-18 2010-09-23 Ac Immune S.A. Method for therapeutic use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STOLTZNER et al., American Journal of Pathology, 2000, Vol. 156, No. 2, Pages 489-499. *

Also Published As

Publication number Publication date
EP2758071A1 (en) 2014-07-30
EA201400376A1 (ru) 2014-09-30
US20140314837A1 (en) 2014-10-23
EA032494B1 (ru) 2019-06-28
JP2014531455A (ja) 2014-11-27
WO2013044147A1 (en) 2013-03-28
HUE041277T2 (hu) 2019-05-28
AU2012312126A1 (en) 2014-03-27
PT2758071T (pt) 2019-01-11
CN109847058A (zh) 2019-06-07
JP6110861B2 (ja) 2017-04-05
ES2712951T3 (es) 2019-05-16
PH12014500657A1 (en) 2014-05-05
IL231564A0 (en) 2014-04-30
PL2758071T3 (pl) 2019-08-30
CA2811188A1 (en) 2013-03-23
MY169574A (en) 2019-04-22
DK2758071T3 (en) 2019-02-18
MX2014003325A (es) 2014-05-21
KR20160005380A (ko) 2016-01-15
NZ622653A (en) 2015-12-24
CA2811188C (en) 2020-04-28
SG11201400795UA (en) 2014-10-30
ZA201402071B (en) 2017-08-30
BR112014006871A2 (pt) 2017-04-04
TR201901846T4 (tr) 2019-03-21
SI2758071T1 (sl) 2019-01-31
US20240270829A1 (en) 2024-08-15
KR102129220B1 (ko) 2020-07-02
MX350928B (es) 2017-09-26
KR20190035948A (ko) 2019-04-03
CN104039346A (zh) 2014-09-10
KR20160099732A (ko) 2016-08-22
EP2758071B1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
US20240270829A1 (en) Vaccine Therapy
JP5249043B2 (ja) 治療ワクチン
RU2551782C2 (ru) Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
US8926983B2 (en) Method for improving memory in AD patients
JP2019163268A (ja) 病理学的タウタンパク質の免疫学的標的化方法
US20100284909A1 (en) Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
NZ622653B2 (en) Vaccine therapy for the treatment of memory and/or cognitive impairments in subjects with down’s syndrome
HK1197732A (en) Vaccine therapy
HK1197732B (en) Vaccine therapy
RS54074B1 (sr) Metode i kompozicije koje sadrže supramolekulske konstrukte

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)